Antiviral Monocytes Increase Prior to Detectable HIV-1 Rebound Viremia.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40628395.
- Also identified by DOI 10.1093/infdis/jiaf367 and PMC identifier 12614978.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The persistence of human immunodeficiency virus 1 (HIV-1) proviruses in latently infected cells allows viremia to resume upon treatment cessation. To characterize the resulting immune response, we compared plasma proteomics and single-cell transcriptomics of peripheral blood mononuclear cells before, during, and after detectable plasma viremia. We observed unique transcriptional signatures prior to viral rebound, including a significant increase in CD16++ monocytes with increased antiviral gene expression. Inflammatory proteins were identified in plasma after detectable rebound. Identifying early signals of imminent viral rebound after treatment cessation will aid in the development of strategies to prolong time to viral rebound and cure HIV-1.
Medical subject headings
- Viremia
- Monocytes
- HIV-1
- HIV Infections